The-loop C region of the murine 5-HT3A receptor contributes to the differential actions of 5-hydroxytryptamine and m-chlorophenylbiguanide

被引:19
作者
Suryanarayanan, A
Joshi, PR
Bikádi, Z
Mani, M
Kulkarni, TR
Gaines, C
Schulte, MK
机构
[1] Univ Alaska, Dept Chem & Biochem, Fairbanks, AK 99775 USA
[2] Inst Chem, Dept Mol Pharmacol, Chem Res Ctr, H-1525 Budapest, Hungary
[3] Uni Louisana, Coll Pharm, Dept Basic Pharmaceut Sci, Monroe, LA 71209 USA
关键词
D O I
10.1021/bi050661e
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sequence and predicted structural similarities between members of the Cys loop superfamily of ligand-gated ion channel receptors and the acetylcholine binding protein (AChBP) suggest that the ligand-binding site is formed by six loops that intersect at subunit interfaces. We employed site-directed mutagenesis to investigate the role of amino acids from the loop C region of the murine 5-HT3ASR in interacting with two structurally different agonists, serotonin (5-HT) and m-chlorophenylbiguanide (mCPBG). Mutant receptors were evaluated using radioligand binding, two-electrode voltage clamp, and immunofluorescence studies. Electrophysiological assays were employed to identify changes in response characteristics and relative efficacies of mCPBG and the partial agonist, 2-methyl 5-HT (2-Me5-HT). We have also constructed novel 5-HT and mCPBG docked models of the receptor binding site based on homology models of the AChBP. Both ligand-docked models correlate well with results from mutagenesis and electrophysiological assays. Four key amino acids were identified as being important to ligand binding and/or gating of the receptor. Among these, I228 and D229 are specific for effects mediated by 5-HT compared to mCPBG, indicating a differential interaction of these ligands with loop C. Residues F226 and Y234 are important for both 5-HT and mCPBG interactions. Mutations at F226,1228, and Y234 also altered the relative efficacies of agonists, suggesting a role in the gating mechanism.
引用
收藏
页码:9140 / 9149
页数:10
相关论文
共 47 条
[1]   A mutational analysis of the acetylcholine receptor channel transmitter binding site [J].
Akk, G ;
Zhou, M ;
Auerbach, A .
BIOPHYSICAL JOURNAL, 1999, 76 (01) :207-218
[2]   Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors [J].
Arias, HR .
NEUROCHEMISTRY INTERNATIONAL, 2000, 36 (07) :595-645
[3]   Electrophysiological consequences of ligand binding to the desensitized 5-HT3 receptor in mammalian NG108-15 cells [J].
Bartrup, JT ;
Newberry, NR .
JOURNAL OF PHYSIOLOGY-LONDON, 1996, 490 (03) :679-690
[4]   Cation-π interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors:: The anomalous binding properties of nicotine [J].
Beene, DL ;
Brandt, GS ;
Zhong, WG ;
Zacharias, NM ;
Lester, HA ;
Dougherty, DA .
BIOCHEMISTRY, 2002, 41 (32) :10262-10269
[5]   Analysis of the ligand binding site of the 5-HT3 receptor using site directed mutagenesis: Importance of glutamate 106 [J].
Boess, FG ;
Steward, LJ ;
Steele, JA ;
Liu, D ;
Reid, J ;
Glencorse, TA ;
Martin, IL .
NEUROPHARMACOLOGY, 1997, 36 (4-5) :637-647
[6]   Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors [J].
Brejc, K ;
van Dijk, WJ ;
Klaassen, RV ;
Schuurmans, M ;
van der Oost, J ;
Smit, AB ;
Sixma, TK .
NATURE, 2001, 411 (6835) :269-276
[7]   Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures [J].
Celie, PHN ;
van Rossum-Fikkert, SE ;
van Dijk, WJ ;
Brejc, K ;
Smit, AB ;
Sixma, TK .
NEURON, 2004, 41 (06) :907-914
[8]  
Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924
[9]   A 2ND GENERATION FORCE-FIELD FOR THE SIMULATION OF PROTEINS, NUCLEIC-ACIDS, AND ORGANIC-MOLECULES [J].
CORNELL, WD ;
CIEPLAK, P ;
BAYLY, CI ;
GOULD, IR ;
MERZ, KM ;
FERGUSON, DM ;
SPELLMEYER, DC ;
FOX, T ;
CALDWELL, JW ;
KOLLMAN, PA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1995, 117 (19) :5179-5197
[10]   5-HT3 Receptors [J].
Costall, Brenda ;
Naylor, Robert J. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2004, 3 (01) :27-37